Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faricimab for Polypoidal Choroidal Vasculopathy (Japan, Phase IIIb/IV)
jRCT2031220231Phase 4Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Apr 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 4, open-label, single-arm trial of faricimab in polypoidal choroidal vasculopathy (PCV), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Change from baseline in BCVA at Weeks 40, 44, and 48. Started Apr 2023; status: completed.
02
Drugs
faricimab
03
Conditions
polypoidal choroidal vasculopathy (PCV)
Beyond the preview
Go deeper on jRCT2031220231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220231.